Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(19 sites)
United States
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California University of Colorado - Aurora Cancer Center, Aurora, Colorado Sarah Cannon - Colorado Blood Cancer Institute, Denver, Colorado University of Chicago, Chicago, Illinois Dana Farber Cancer Institute, Boston, Massachusetts Roswell Park Comprehensive Cancer Center, Buffalo, New York Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York Weill Medical College of Cornell University, New York, New York Children's Hospital of Philadelphia, Philadelphia, Pennsylvania Sarah Cannon - HCA Research Institute, Nashville, Tennessee Sarah Cannon - St. David's South Austin Medical Center, Austin, Texas MD Anderson Cancer Center, Houston, Texas Sarah Cannon - Texas Transplant Institute at Methodist Hospital, San Antonio, Texas University of Wisconsin Carbone Cancer Center, Madison, Wisconsin France
CHU de Nantes - Hôtel-Dieu, Nantes Hôpital Saint Louis, Unité d'Hématologie Adolescents et Jeunes Adultes Département d'Hématologie, Paris Hôpital Robert Debré - Service d'hémato-immunologie, Paris Hôpital Lyon Sud, Pierre-Bénite CHU Rennes - Hopital Pontchaillou, Rennes